Pluronic F-68 Montmorillonite As A Drug Delivery Vehicle For Extended Release Of Venlafaxine Hydrochloride

Abstract

Short half-life and low bioavailability of Venlafaxine hydrochloride (VF), an antidepressant drug, necessitates the frequent administration of VF tablets in a day in order to maintain adequate drug concentration in blood plasma. This generates the need for the development of formulations which could prolong the release of VF and reduce the multiple dosages. The present work explores the combination of Montmorillonite (Mt) with Pluronic F-68 (PF-68) (OrganoMT) for oral delivery of VF. The effect of various parameters including pH of aqueous drug solution, contact time and initial drug concentration on drug loading capacity of OrganoMT has been studied. The synthesized OrganoMT-VF complexes were characterized by various suitable techniques. XRD studies indicated that the VF molecules were intercalated within the OrganoMT layers. In vitro release behavior of VF from OrganoMT-VF complexes shows an extended-release pattern for a period of 30 h and reaches upto 70% and 60% compared to pure VF having complete release time of 5.5 h and 3.5 h in simulated gastric and intestinal fluid respectively. Various kinetic models were employed to elucidate the drug release mechanism where the best fitting was obtained with Korsmeyer Peppas model. The results suggest the possibility of designing an oral extended controlled release formulation for VF to minimize its administration frequency thereby increasing the effectiveness of drug. This improves patient compliance by reducing the dose from 4 times in 24 h to once in 24 h.

Key words

Pluronic F-68 - Venlafaxine hydrochloride - Oral extended release - Montmorillonite

Publikationsverlauf

Eingereicht: 31. August 2022

Angenommen: 26. Januar 2023

Artikel online veröffentlicht:
28. April 2023

• References

• 1 Wang X, Yumin D, Luo J. Biopolymer/Montmorillonite Nanocomposite: Preparation, Drug-Controlled Release Property and Cytotoxicity. Nanotechnology 2008; 19: 065707
• 2 Aguzzi PC, Viseras C, Caramella C. Use of Clays as Drug Delivery Systems: Possibilities and Limitations. App Clay Sci 2007; 36: 22-36
• 3 Theng BKG. The Chemistry of Clay-Organic Reaction Adam Hilger; London. 1974
• 4 Lee SM, Tiwari D. Organo and Inorgano-Organo-Modified Clays in the Remediation of Aqueous Solutions: An Overview. App Clay Sci 2012; 59-60: 84-102
• 5 Chua YC, Lu X. Polymorphism Behavior of Poly(ethylene naphthalate)/Clay Nanocomposites:  Role of Clay Surface Modification. Langmuir 2007; 23: 1701-1710
• 6 Chen BY, Lee YH, Lin WC. et al. Understanding the Characteristics of L-ascorbic acid-montmorillonite Nanocomposite: Chemical Structure and Biotoxicity. Biomed Eng Appl Basis Commun 2006; 18: 30-36
• 7 Kaur M, Datta M. Adsorption Characteristics of Acid Orange 10 from Aqueous Solutions onto Montmorillonite Clay. Adsorp Sci Tech 2011; 29: 301-318
• 8 Guegan R, Gautier M, Beny JM. et al. Adsorption of a C10E3 Non-ionic Surfactant on a Ca-Smectite. Clays Clay Miner 2009; 57: 502-509
• 9 Klamerus KJ, Maloney K, Rudolph RL. et al. Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite Clin Pharma 1992; 32: 716-724
• 10 Haskins JT, Moyer JA, Muth EA. et al. DMI, Wy-45,030, Wy-45,881 and Ciramadol Inhibit Locus Coeruleus Neuronal Activity. Pharma 1985; 115: 139-146
• 11 Tang J, Bian Z, Hu J. et al. The Effect of a P123 Template in Mesopores of Mesocellular Foam on the Controlled-release of Venlafaxine. Int J Pharma 2012; 424: 89-97
• 12 Doddayya H, Patil SS, Kaledhele A. et al. Effect of Gum Rosin And Ethyl Cellulose On In Vitro Release Of Venlafaxine Hydrochloride From Hydrophilic Matrix Tablets. Int J Pharm Biol Sci Arch 2011; 2: 980-988
• 13 Abdeen R, Salahuddin N. Modified Chitosan-Clay Nanocomposite as a Drug Delivery System Intercalation and In Vitro Release of Ibuprofen. J Chem 2013; 1-9
• 14 Sahu A, Kasoju N, Goswami P. et al. Encapsulation of Curcumin in Pluronic Block Copolymer Micelles for Drug Delivery Applications. J Biomater Appl 2010; 25: 619-639
• 15 Xie Y, Li G, Yuan X. et al. Preparation and In Vitro Evaluation of Solid Dispersions of Total Flavones of Hippophae rhamnoides L. AAPS Pharma Sci Tech 2009; 10: 631-640
• 16 Dash S, Murthy PN, Nath L. et al. Kinetic Modeling on Drug Release From Controlled Drug Delivery Systems. Acta Poloniae Pharmaceutica Drug Res 2010; 67: 217-223
• 17 Gaber DM, Nafee N, Adallah OY. Mini-Tablets Versus Pellets As Promising Multiparticulate Modified Release Delivery Systems For Highly Soluble Drugs. Int J Pharm 2015; 488: 86-94
• 18 Peppas NA. Devices Based on Intelligent Biopolymers for Oral Protein Delivery. Int J Pharm 2004; 277: 11
• 19 Venditti I, Fontana L, Fraoddi I. et al. Direct Interaction of Hydrophilic Gold Nanoparticles With Dexamethasone Drug: Loading And Release Study. Colloid Interf Sci 2014; 418: 52-60
• 20 Zampori L, Stampino PG, Cristiani C. et al. Intercalation of poly(ethylene-oxides) in Montmorillonite: Tailor-made Nanocontainers for Drug Delivery Systems. Appl Clay Sci 2010; 50: 266
• 21 Sivalakshmidevi A, Vyas K, Rao SM. et al. A Monoclinic Polymorph of Venlafaxine Hydrochloride. Acta Cryst Sect E 2002; 58: o1072-o1074
• 22 Depan D, Kumar AP, Singh RP. Cell proliferation and Controlled Drug Release Studies of Nanohybrids based on Chitosan-g-lactic Acid and Montmorillonite. Acta Biomaterialia 2009; 5: 93-100
• 23 Suresh R, Borkar SN, Sawant VA. et al. Nanoclay Drug Delivery System. Int J Pharm Sci Nanotech 2010; 3: 901-905
• 24 Rodrigues LAS, Figueiras A, Veiga F. et al. The Systems Containing Clays and Clay Minerals From Modified Drug Release: A Review. Colloids Surf B 2013; 103: 642-651
• 25 Murray HH. Traditional and New Applications For Kaolin, Smectite, And Palygorskite: A General Overview. Appl Clay Sci 2000; 17: 207-221
• 26 Yuan Q, Shah J, Hein S. et al. Controlled And Extended Drug Release Behavior of Chitosan-Based Nanoparticle Carrier. Acta Biomaterialia 2010; 6: 1140-1148
• 27 Nunes CD, Vaz PD, Fernandes AC. et al. Loading and Delivery Of Sertraline Using Inorganic Micro And Mesoporous Materials. Eur J Pharm Biopharm 2007; 66: 357-365
• 28 Joshi GV, Patel HA, Kevadiya BD. et al. Montmorillonite Intercalated with Vitamin B1 As Drug Carrier. Appl Clay Sci 2009; 45: 248-253
• 29 Seki Y, Yurdakoc K. Equilibrium, Kinetics and Thermodynamic Aspects of Promethazine Hydrochloride Sorption by Iron Rich Smectite. Colloids and Surfaces A: Physicochem Eng Aspects 2009; 340: 143-148
• 30 Chen Y, Zhou A, Liu B. et al. Tramadol Hydrochloride/Montmorillonite Composite: Preparation and Controlled Drug Release. App Clay Sci 2010; 49: 108-112
• 31 Iliescu RI, Andronescu E, Voicu G. et al. Hybrid Materials Based On Montmorillonite And Citostatic Drugs: Preparation And Characterization. App Clay Sci 2011; 52: 62-68
• 32 Bergaya F, Jaber M, Lambert JF. Clays and Clay Minerals, 2011; Chapter 1. In: Galimberti M, (Ed.), “Rubber-Clay Nanocomposites: Science, Technology and Applications”. John Willey & Sons; 3-44
• 33 Hongping H, Lingya M, Jianxi Z. et al. Synthesis of Organoclays: A Critical Review and Some Unresolved Issues. App Clay Sci 2014; 100: 22-28
• 34 Lagaly G, Dékany I. Colloid Clay Science, 2013; Chapter 8, Handbook of Clay Science, In: Bergaya F, Lagaly G (Eds.), 2nd edition, “Developments in Clay Science”, vol. 5A. Elsevier; 243-345
• 35 Jain S, Datta M. Montmorillonite-alginate microspheres as a delivery vehicle for oral extended release of Venlafaxine hydrochloride. J Drug Deliv Sci Technol 2016; 33: 149-156
• 36 Jain S, Datta M. Montmorillonite-PLGA Nanocomposites as an Oral Extended Drug Delivery Vehicle for Venlafaxine Hydrochloride. Appl Clay Sci 2014; 99C: 42-47
• 37 Jain S, Datta M. Naturally Occuring Clay, Montmorillonite, As a Drug Delivery Vehicle for In Vitro Extended Release of Venlafaxine Hydrochloride. Eur Chem Bull 2014; 3: 672-681
• 38 Entsuah R, Chitra R. A Benefit-Risk Analysis of Once-Daily Venlafaxine Extended Release (XR) And Venlafaxine Immediate Release (IR) in Outpatients with Major Depression. Psychopharma Bull 1997; 33: 671-676
• 39 Eupen JTH, Westheim R, Deija MA. et al. The Solubility Behaviour and Thermodynamic Relations of The Three Forms of Venlafaxine Free Base. Int J Pharm 2009; 368: 146-153
• 40 Olver JS, Burrows GD, Norman TR. Third-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?. CNS Drugs 2001; 15: 941-954
• 41 Harrison CL, Ferrier N, Young AHJ. Tolerability of High-Dose Venlafaxine in Depressed Patients. J Psychopharma 2004; 18: 200-204
• 42 Patel HA, Shah S, Shah DO. et al. Sustained Release of Venlafaxine from Venlafaxine–Montmorillonite–Polyvinylpyrrolidone Composites. App Clay Sci 2011; 51: 126-130
• 43 Senthil A, Thakkar HR, Kumar VDM. Design and Optimization of Mucoadhesive Microspheres of Venlaflaxine Hcl Using 23 Full Factorial Designs. Der Pharmacia Lettre 2011; 3: 202-211
• 44 Ajit I, Senthil A, Rahul B. et al. Formulation and Evaluation of Venlafaxine Hydrochloride Mucoadhesive Buccal Tablets. Int Res J Pharma 2012; 3: 226-231
• 45 Meng N, Zhou NL, Zhang SQ. et al. Controlled Release and Antibacterial Activity Chlorhexidine Acetate (CA) Intercalated in Montmorillonite. Int J Pharm 2009; 382: 45-49
• 46 Bessar H, Venditti I, Benassi L. et al. Functionalized Gold Nanoparticles for Topical Delivery of Methotrexate for the Possible Treatment of Psoriasis. Colloids Surf B Biointerfaces 2016; 141: 141-147
• 47 Malewar N, Avachat M, Kulkarni S. et al. Design And Evaluation Of Novel Barrier Layer Technologies for Controlling Venlafaxine Hydrochloride Release From Tablet Dosage Form. Pharm Dev Technol 2015; 20: 588-597
• 48 Shah S, Pal A, Kaushik VK. et al. Preparation and Characterization of Venlafaxine Hydrochloride-loaded Chitosan Nanoparticles and In-vitro Release of Drug. Appl Polym Sci 2009; 112: 2876-2887
• 49 Fraoddi I, Venditti I, Cametti C. et al Functional Polymeric Nanoparticles for Dexamethasone Loading and Release. Colloids Surf B Biointerfaces 2012; 93: 59-66